India Pharma Outlook Team | Thursday, 31 July 2025
Everest Group, a leading global research and consulting firm, named Indegene a Leader in Life Sciences AI and Analytics Services for Commercial PEAK Matrix Assessment 2025.
Everest Group acknowledged Indegene’s wide-ranging AI and Analytics solutions across the life sciences commercial function, reinforcing its position as a trusted transformation partner for life sciences organizations.
Everest Group also commended Indegene’s continued efforts to embed Generative AI (GenAI) and Agentic AI capabilities across its commercial solutions portfolio, including investments in conversational AI, content summarization engines, and multi-agent orchestration frameworks to drive intelligent, contextualized automation.
Also Read: How Robotic Assisted Surgery Is Redefining Precision in Kidney Transplants
The report highlighted Indegene’s unique ability to combine its AI and Analytics capabilities with deep domain knowledge to deliver contextualized commercial solutions across a broad portfolio of therapy areas, including specifically tailored solutions for emerging therapy areas such as specialty care, oncology and rare diseases.
“The growing emphasis on patient - and HCP-centricity to deliver superior customer experiences has modernized commercialization strategies, placing data, analytics, and AI at the core of life sciences enterprises' go-to-market efforts. As a result, they are turning to strategic partners with domain-led digital expertise and scalable technology solutions to navigate the evolving landscape,” said Durga Ambati, Practice Director at Everest Group.
“Indegene’s broad portfolio of solutions within its NEXT platform, as well as its continued investments in embedding GenAI and Agentic AI across its capabilities, are well-complemented by its diverse therapeutic knowledge and strong market-facing assets. These factors have led to Indegene earning a Leader position in Everest Group’s Life Sciences AI and Analytics Services for Commercial PEAK Matrix Assessment 2025.”
Indegene’s unified, enterprise-wide AI approach embeds production-ready solutions across commercial operations. This strategy is already helping life sciences companies achieve significant operational efficiencies and productivity gains, and accelerating their journey towards being future-ready.
Also Read: The Future of Genomic Sequencing: Trends That Will Define the Next Decade
“Advancements in AI and analytics are enabling life sciences companies to modernize and transform their business operations with an AI-first, data-driven approach”, said Vivek Ghai, EVP-Enterprise Commercial Solutions, Indegene. “Our focus is on helping clients scale AI responsibly - prioritizing use cases that drive measurable outcomes, integrating seamlessly with enterprise ecosystems, and delivering solutions that are not just innovative, but production-ready from day one. Everest Group’s recognition validates our ability to translate advanced AI into real-world value for our clients.”
Everest Group assessed 30 service providers on their AI and Analytics vision, capabilities, and market impact. The evaluation criteria included vision and strategy, scope of services, innovation and investments, delivery footprint, market adoption, portfolio mix, and client value delivered.
Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech, and medical device companies commercialize their products. Its client base includes the world’s top 20 biopharma companies, many emerging biotech firms, and medical device companies. Indegene has around 5,000 employees worldwide, 9 operations hubs and 19 offices across North America, Europe, and Asia.
